Strategies for early detection of cardiotoxicities from anticancer therapy in adults: Evolving imaging techniques and emerging serum biomarkers

Nausheen Akhter, Gillian Murtagh, Clyde Yancy*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

Significant advances have been made in detecting cancer therapeutics-related cardiac dysfunction with serum biomarkers, cardiovascular MRI, echocardiography and multi-modality approaches. Serum biomarkers, notably cardiac troponins and natriuretic peptides, have been evaluated for their prognostic ability in predicting left ventricular dysfunction. Imaging modalities, such as cardiovascular MRI and echocardiography, have been used for cardiac surveillance of patients with cancer undergoing chemotherapy. Developments in imaging, specifically myocardial deformation imaging, also known as strain, have been shown to be sensitive tools in detecting early changes in cardiac function. This review aims to synthesize the evidence that supports emerging serum biomarkers and complementary imaging modalities that continue to enhance the detection of cancer therapeutics-related cardiac dysfunction.

Original languageEnglish (US)
Pages (from-to)2093-2103
Number of pages11
JournalFuture Oncology
Volume11
Issue number14
DOIs
StatePublished - Jul 1 2015

Keywords

  • CMR
  • CTRCD
  • MPO
  • biomarkers
  • cancer therapeutics-related cardiac dysfunction
  • cardiovascular MRI
  • echocardiography
  • highly sensitive Troponin I
  • hsTnI
  • myeloperoxidase
  • myocardial deformation imaging
  • strain imaging

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Strategies for early detection of cardiotoxicities from anticancer therapy in adults: Evolving imaging techniques and emerging serum biomarkers'. Together they form a unique fingerprint.

Cite this